Cash Capital has returned for OnQuality Pharmaceuticals’s latest round, having already participated in a $15m series A in 2019.
OnQuality Pharmaceuticals, a US-based developer of drugs to counteract chemotherapy side effects, secured $20m in series A-plus financing today from investors including Cash Capital, the investment arm of Chinese Academy of Sciences.
Sinovation Ventures, Shiyu Capital, Matrix Partners China, BioTrack Capital and Frees Fund also took part, as did unnamed investors.
Founded in 2018, OnQuality is developing treatments drugs for patients undergoing cancer therapy that lessen side effects associated with current medications.
It will put the money…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
